Effect of direct hemoperfusion using polymyxin B immobilized fiber on inflammatory mediators in patients with severe sepsis and septic shock

International Journal of Artificial Organs

Volumn 31, Issue 10, 2008, Pages 891-897

  Kanesaka, Shigeru ^a,b   Sasaki, J ^a   Kazume, M ^a   Narihara, K ^a   Takahashi, Y ^a  

^a SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^b SHOWA UNIVERSITY NORTHERN YOKOHAMA HOSPITAL   (Japan)

Author keywords

Direct hemoperfusion; Hemodynamics; Inflammatory mediators; Polymyxin B immobilized fiber; Septic shock

Indexed keywords

BLOOD; BLOOD PRESSURE;

BACTERIAL INFECTIONS; DIRECT HEMOPERFUSION; HAEMODYNAMICS; HEMOPERFUSION; INFLAMMATORY MEDIATORS; MEAN AGES; POLYMYXIN B; POLYMYXIN B IMMOBILIZED FIBER; POST TREATMENT; SEPTIC SHOCKS;

HEMODYNAMICS;

DOPAMINE; ENDOTOXIN; INTERLEUKIN 6; NAFAMSTAT MESILATE; POLYMYXIN B; PYRUVIC ACID;

ADULT; APACHE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GRAM NEGATIVE INFECTION; HEMODYNAMICS; HEMOPERFUSION; HUMAN; IMMOBILIZATION; INFLAMMATION; LIMULUS LYSATE TEST; MEAN ARTERIAL PRESSURE; MEDIATOR RELEASE; MONOCYTE; PULSE PRESSURE; RANK SUM TEST; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK; SYSTEMIC VASCULAR RESISTANCE; TURBIDIMETRY; URINE VOLUME;

EID: 59549090435     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880803101005     Document Type: Article

References (23)

1. Astiz ME, Rackow EC. Septic shock. Lancet 1998; 351: 1501-5.
2. Alberti C, Brun-Buisson C, Goodman SV, Guidici D, Granton J, Moreno R, Smithies M, Thomas O, Artigas A, Le Gall JR; European Sepsis Group. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 2003; 168: 77-84.
3. Nasraway SA. The problems and challenges of immunotherapy in sepsis. Chest 2003; 123 (Suppl): S451-9.
4. Kodama M, Tani T, Hanasawa K, et al. Treatment of sepsis by plasma endotoxin removal: hemoperfusion using a polymyxin-B immobilized column. J Endotoxin Res 1997; 4: 293-300.
5. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. The ACCP/SCCM Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644-55.
6. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Crit Care Med 1998; 26: 1793-1800.
7. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32: 858-73.
8. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, Peterson E, Tomlanovich M; Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-77.
9. Kojika M, Sato N, Yaegashi Y, Suzuki Y, Suzuki K, Nakae H, Endo S. Endotoxin adsorption therapy for septic shock using polymyxin B-immobilized fibers (PMX): evaluation by high-sensitivity endotoxin assay and measurement of the cytokine production capacity. Ther Apher Dial 2006; 10: 12-8.
10. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APA-CHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
11. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 1989; 321: 280-7.
12. Stegmyr BG, Banga R, Berggren L, Norda R, Rydvall A, Vikerfors T. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit Care Med 2003; 31: 1730-36.
13. Busund R, Koukline V, Utrobin U, Nedashkovsky E. Plasmapheresis in severe sepsis and septic shock: a prospective, randomized, controlled trial. Intensive Care Med 2002; 28: 1434-9.
14. Annane D, Sebille V, Charpentier C, Bollaert PE, Fran&ois B, Korach JM, Capellier G, Cohen Y, Azoulay E, Troché G, Chaumet-Riffaut P, Bellissant E. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71.
15. Tsujimoto H, Ono S, Hiraki S, Majima T, Kawarabayashi N, Sugasawa H, Kinoshita M, Hiraide H, Mochizuki H. Hemoperfusion with polymyxin B-immobilized fibers reduced the number of CD16+CD14+ monocytes in patients with septic shock. J Endotoxin Res 2004; 10: 229-37.
16. Vincent JL, Laterre P-F, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, Nakamura H, John S. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 2005; 23: 400-5.
17. Nakamura T, Kawagoe Y, Matsuda T, Ebihara I, Koide H. Effects of polymyxin B-immobilized fiber hemoperfusion on amino acid imbalance in septic encephalopathy. Blood Purif 2003; 21: 282-6.
18. Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I. Polymyxin B binds to anandamide and inhibits its cytotoxic effect. FEBS Lett 2000; 470: 151-5.
19. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS): a prospective study. JAMA 1995; 273: 117-123.
20. Brun-Buisson C, Doyon F, Carlet J, Dellamonica P, Gouin F, Lepoutre A, Mercier JC, Offenstadt G, Rognier B. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults: a multicenter prospective study in intensive care units. JAMA 1995; 274: 968-74.
21. Gutierrez G, Wulf ME. Lactic acidosis in sepsis: a commentary. Intensive Care Med 1996; 22: 6-16.
22. Suzuki H, Nemoto H, Nakamoto H, Okada H, Sugahara S, Kanno Y, Moriwaki K. Continuous hemodiafiltration with polymyxin-B immobilized fiber is effective in patients with sepsis syndrome and acute renal failure. Ther Apher 2002; 6: 234-40.
23. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr; Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.